Improving ILD Diagnosis and Predicting Clinical Progression with the Envisia Genomic Classifier

October 18, 2022 from 1:45 pm 2:30 pm CDT

Supported By: Veracyte, Inc.

Program Description

In this session, speakers will discuss updated IPF/PPF guidelines, key utility data, and the role of the Envisia Genomic Classifier in the diagnosis and prognosis of ILD. New data will be presented that demonstrates how the Envisia Classifier can predict clinical progression in fibrotic interstitial lung disease. Speakers will also review Veracyte’s portfolio in lung nodule patient management including a preview of a novel nasal swab classifier.

Location: Learning Theater 3


William Bulman, MD
Veracyte, Inc
Medical Director, Pulmonary
San Francisco, CA

Mary Beth Scholand, MD
University of Utah
Associate Professor Pulmonary Medicine
Farmington, UT

Sandeep Bansal, MD, FCCP, FACP
Penn Highlands Healthcare
The Lung Center and Interventional Pulmonology
Medical Director
DuBois, PA